HRS-9057
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 09, 2026
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
(clinicaltrials.gov)
- P2 | N=118 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure
January 06, 2026
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
(clinicaltrials.gov)
- P2 | N=118 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
November 18, 2025
A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
(clinicaltrials.gov)
- P1 | N=25 | Completed | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Oct 2025 | Trial primary completion date: Sep 2024 ➔ Oct 2025
Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
July 18, 2024
A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 4
Of
4
Go to page
1